Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

@inproceedings{Jankowitz2011PrognosticUO,
  title={Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer},
  author={Rachel C. Jankowitz and Kristine L. Cooper and Mark G. Erlander and Xiao-Jun Ma and Nicole C. Kesty and Hongying Li and Mamatha Chivukula and Adam M. Brufsky},
  booktitle={Breast Cancer Research},
  year={2011}
}
Breast Cancer Index (BCI) combines two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene molecular grade index (MGI), that assess estrogen-mediated signalling and tumor grade, respectively. BCI stratifies early-stage estrogen-receptor positive (ER+), lymph-node negative (LN-) breast cancer patients into three risk groups and provides a continuous assessment of individual risk of distant recurrence. Objectives of the current study were to validate BCI in a clinical case series and to… CONTINUE READING